Onco-Summaries: Daily Oncology Updates at a Glance

21/08/2025

In a $350M deal, Kite to acquire Interius BioTherapeutics (Ref)

Kite (a Gilead Company) entered into a definitive agreement to acquire Interius BioTherapeutics developing in vivo CAR therapeutics for $350 million.

• Interius’ off-the-shelf and personalized approach is designed to be delivered via a single IV infusion, eliminating the need for preconditioning chemotherapy and complex cell processing

  
  

• Under the terms of the agreement, Kite will acquire all of the outstanding share capital of Interius for a total of $350 million in cash consideration, subject to customary adjustments, which is payable at closing

  
  

• Closing of the transaction is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions